Literature DB >> 18638432

Treating difficult crystal pyrophosphate dihydrate deposition disease.

Nadia Announ1, Pierre-André Guerne.   

Abstract

Calcium pyrophosphate dihydrate deposition disease is a common and potentially severe metabolic arthropathy. Early disease (in patients </= 60 years old) requires a search for one of the associated metabolic conditions, particularly hemochromatosis. Treatment is primarily symptomatic (no drug is known to prevent the progression of articular destruction). Nonsteroidal anti-inflammatory drugs and intra-articular or systemic glucocorticoids (in small amounts if use is prolonged) are the most useful treatments. Colchicine can be effective to treat recurring pseudogout, and magnesium can be effective on a preventive basis. Methotrexate showed interesting effectiveness in a small, uncontrolled series, and it can be used in the event of failure of the other treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18638432     DOI: 10.1007/s11926-008-0037-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  31 in total

Review 1.  Management of crystal arthritis.

Authors:  E Pascual
Journal:  Rheumatology (Oxford)       Date:  1999-10       Impact factor: 7.580

Review 2.  Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs.

Authors:  S B Abramson
Journal:  Curr Opin Rheumatol       Date:  1992-06       Impact factor: 5.006

3.  Lack of association between chondrocalcinosis and increased risk of cartilage loss in knees with osteoarthritis: results of two prospective longitudinal magnetic resonance imaging studies.

Authors:  T Neogi; M Nevitt; J Niu; M P LaValley; D J Hunter; R Terkeltaub; L Carbone; H Chen; T Harris; K Kwoh; A Guermazi; D T Felson
Journal:  Arthritis Rheum       Date:  2006-06

4.  Calcium pyrophosphate crystal deposition is not always 'wear and tear' or aging.

Authors:  G D Wright; M Doherty
Journal:  Ann Rheum Dis       Date:  1997-10       Impact factor: 19.103

5.  Prospective use of intramuscular triamcinolone acetonide in pseudogout.

Authors:  D W Roane; M D Harris; M T Carpenter; D R Finger; M J Jarek; J A Alloway; A R Erickson; W E Venanzi; T J Drehmer
Journal:  J Rheumatol       Date:  1997-06       Impact factor: 4.666

Review 6.  Molecular and cellular effects of methotrexate.

Authors:  M Seitz
Journal:  Curr Opin Rheumatol       Date:  1999-05       Impact factor: 5.006

7.  A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain.

Authors:  Robert J Goldberg; Joel Katz
Journal:  Pain       Date:  2007-03-01       Impact factor: 6.961

8.  Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis.

Authors:  Christian A Hudert; Karsten H Weylandt; Yan Lu; Jingdong Wang; Song Hong; Axel Dignass; Charles N Serhan; Jing X Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-17       Impact factor: 11.205

9.  Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities.

Authors:  Y Yazici; T Sokka; H Kautiainen; C Swearingen; I Kulman; T Pincus
Journal:  Ann Rheum Dis       Date:  2004-06-18       Impact factor: 19.103

10.  Hypomagnesemia associated with chondrocalcinosis: a cross-sectional study.

Authors:  Pascal Richette; Ghazi Ayoub; Sophie Lahalle; Eric Vicaut; Abdul-Monem Badran; Francisca Joly; Bernard Messing; Thomas Bardin
Journal:  Arthritis Rheum       Date:  2007-12-15
View more
  8 in total

Review 1.  Cartilage diseases.

Authors:  Yamini Krishnan; Alan J Grodzinsky
Journal:  Matrix Biol       Date:  2018-05-24       Impact factor: 11.583

2.  Treatment and management of pseudogout: insights for the clinician.

Authors:  Paul Macmullan; Geraldine McCarthy
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

Review 3.  Pathophysiology of articular chondrocalcinosis--role of ANKH.

Authors:  Abhishek Abhishek; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2010-11-23       Impact factor: 20.543

4.  Calcium pyrophosphate dihydrate deposition in the trochanteric hip bursa presenting as acute hip pain.

Authors:  Omer Salar; Fizza Mushtaq; Mushtaq Ahmed
Journal:  BMJ Case Rep       Date:  2012-07-10

Review 5.  HFE-related hemochromatosis: an update for the rheumatologist.

Authors:  Emma Husar-Memmer; Andreas Stadlmayr; Christian Datz; Jochen Zwerina
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

6.  Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?

Authors:  Eliseo Pascual; Mariano Andrés; Francisca Sivera
Journal:  Arthritis Res Ther       Date:  2015-04-01       Impact factor: 5.156

7.  Clinical, radiological, and biochemical characteristics in patients with diseases mimicking polymyalgia rheumatica.

Authors:  Hidekatsu Yanai; Hiroshi Yoshida; Norio Tada
Journal:  Clin Interv Aging       Date:  2009-10-12       Impact factor: 4.458

Review 8.  Treatment of nongout joint deposition diseases: an update.

Authors:  Tristan Pascart; Pascal Richette; René-Marc Flipo
Journal:  Arthritis       Date:  2014-05-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.